spatial omics market is estimated to be valued at USD 315.5 Mn in 2024 and with CAGR of 9.4% over the forecast period 2024-2031. The growth of the market can be attributed to advancements in biological microscopy techniques and increasing adoption of spatial genomics in pharmaceutical and biotech companies. Furthermore, technological developments such as introduction of cryogenic microscopy techniques for better tissue preservation is fueling the market growth.
Market Dynamics:
The growth of the spatial omics market is majorly driven by advancements in biological microscopy techniques and increasing spending on spatial genomics by pharmaceutical and biotech companies. Microscopy techniques such as light sheet fluorescence microscopy and cryo electron microscopy provide high-resolution imaging at single-cell level. This has increased the adoption of spatial omics technologies by research laboratories for developing spatially resolved molecular maps at cellular and tissue level. Moreover, leading pharmaceutical companies are investing heavily on development of spatial genomics assays and instruments to study complex disease mechanisms and identify drug targets. For instance, companies are utilizing spatial omics to map gene expression patterns in tumor microenvironments to develop targeted cancer therapies. The increasing R&D spending on spatial biology is expected to propel the spatial omics market over the forecast period.
Advancements in spatial analysis techniques
Spatial analysis techniques have advanced significantly in recent years which has enabled researchers to analyze biological samples with greater resolution and specificity. Technologies like multiplexed fluorescence imaging and spatial transcriptomics now allow mapping molecular landscapes at single-cell resolution. This has driven more widespread adoption of spatial omics approaches as they provide more insights into cellular heterogeneity and tissue microenvironments.
Increasing funding for spatially resolved omics projects
Governments and private foundations have been increasingly funding large scale spatially resolved 'omics projects. For example, projects like the Human Cell Atlas and Tabula Sarcra are mapping gene expression across multiple human and animal tissues at single-cell resolution. Such large consortium projects have increased awareness of spatial omics and validated its capabilities which is driving more researchers and institutions to invest in relevant technologies and capabilities.
Complexity of spatial omics workflow and data analysis
The spatial omics workflow from tissue sample preparation and sequencing to data analysis is considerably more complex compared to traditional bulk assays. This complexity poses challenges for researchers new to the field and requires specialized expertise at various steps. The lack of standardized and user-friendly analysis tools also increases the barrier for wider adoption.
High costs associated with spatial omics technologies
While spatial resolution provides unique insights, the instruments, reagents and consumables required for spatial omics applications are significantly more expensive than traditional bulk assays. The high initial investment costs and maintenance of spatial analysis instruments like multiplexed fluorescence or mass cytometry imaging systems poses budgetary constraints, especially for smaller labs and research institutions.
Integration with imaging modalities
There is opportunity to further integrate spatial omics data with high-resolution digital pathology imaging. Combining morphological signatures from imaging with molecular profiles from spatial assays could provide a powerful multi-omics view of tissues. This would help bridge the gap between structure and function providing more clinically relevant insights.
Diagnostic and translational applications
As the resolution and scope of spatial omics expands, there is potential to apply the technologies for diagnostic applications in areas like cancer, neurodegeneration and infectious diseases. Being able to map disease at the tissue/cellular level could uncover new subtype classifications and biomarkers. This translational potential will likely drive increased commercialization and market growth.
Link: https://www.coherentmarketinsights.com/market-insight/spatial-omics-market-5186
Key Development
- In November 2023, Stellaromics, a leading provider of in situ spatial multi-omics technology, announced that it had raised US$ 25 million in Series A funding. Plaisance Capital Management and a Silicon Valley-based private family office participated in the Series A round of financing.
- In June 2023, OWKIN and 10x Genomics, Inc., a techbio company, announced a deal to bring 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already received recognition for its groundbreaking work in tumor analysis for therapeutic discovery
- In December 2021, Rebus Biosystems, Inc., a life science technology company, announced the acquisition of EEL Transcriptomics AB's intellectual property and related assay assets. EEL Transcriptomics AB is a privately held company focused on high-plex spatial transcriptomics with single-cell resolution. The terms of the transaction are not being disclosed.
- In March 2021, Rebus Biosystems, Inc. announced the launch of the Rebus Esper spatial omics platform. The new spatial omics platform will enable researchers to gain a deeper understanding of tissue biology, resulting in advances in neurology, cancer, infectious diseases, and immunology.
Key Players: 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode
